Retinal Biologics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2021-2026

Report Code: HCR 40151 Report Format: PDF + Excel (Delivery in 48 Hrs)

Retinal Biologics Market Overview

Retinal Biologics Market size was estimated at $14 billion in 2020 and is expected to grow with a CAGR of 7.3% during the forecast period 2021-2026. Retinal Biologics are bioengineered molecules which implement inside eyes to heal chronic retinal diseases. Retina is a sensitive part of human eyes that receive light and convert light into neural signals and send these signal to brain for visual recognition. There are several disorders related to retinal health including macular degeneration, diabetic retinopathy, infectious retinitis, macular edema, macular hole, retinoblastoma, retinal degeneration, retinoschisis and uveitis etc. Increasing prevalence of age-related macular degeneration (AMD) and diabetes coupled with rising ageing population are major factors driving the growth of the market. Moreover, growing demand for Retinal Biologics to provide treatment for chronic retinal diseases further enhance the overall market demand for Retinal Biologics during the aforesaid period.

Report Coverage

The report: “Retinal Biologics Market – Forecast (2021-2026)”, by IndustryARC, covers an in-depth analysis of the following segments of the Retinal Biologics Market:
By Drug Class: VEGF-A Antagonist, TNF-a Inhibitor.
By Disease Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Others.
By Distribution Channel: Hospital, Pharmacies, Specialty Clinics Online Pharmacies, Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia and Others), Asia Pacific (China, Japan, India, South Korea, Australia & New Zealand and Others), South America(Brazil, Argentina and others), and Rest of the World (Middle East and Africa).

Key Takeaways

  • In 2020, North America dominated the Retinal Biologics Market owing to rising incidence of diabetes.
  • Increasing innovation and development in Retinal Biologics across the globe is driving the market growth of Retinal Biologics. 
  • Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Retinal Biologics Market report.
  • Initial high investment and stringent regulatory process are challenging the growth of the market. 

Retinal Biologics Market Segment Analysis- By Drug Class

Based on the drug class, Retinal Biologics Market is segmented into VEGF-A Antagonist, TNF-a Inhibitor. The TNF-a Inhibitor segment is estimated to dominate the market during the period 2021-2026. This is attributed to its wide use in stopping inflammation and treating diseases such as Macular Degeneration, Uveitis, retinoblastoma. Furthermore, TNF-a inhibition repairs retinal damage and increases corneal wound healing. The VEGF-A Antagonist, segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 6.1% during the period 2021-2026. This is mainly owing to VEGF-A Antagonist are largely tolerated and gives instant result to eye disorders. 

Retinal Biologics Market Segment Analysis- By Disease Indication

Based on the disease indication, Retinal Biologics Market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. In 2020, Diabetic Retinopathy is estimated to hold major share in the market. This is mainly since diabetic retinopathy is the leading cause of vision loss globally. Moreover, according to, the International Diabetes Federation, extremely consequences diabetes mellitus is increasing from 463 million in 2019 to 700 million in 2045 also contributing to the dominance of this segment. Also, Macular Degeneration is projected to grow with a CAGR of 6.5% over the period 2021-2026. This is owing to it being a leading cause of severe, or permanent vision loss among people over the age of 60.



Retinal Biologics Market Segment Analysis- By Geography
North America dominated the Retinal Biologics market share accounting for 41% of the market in 2020. This is mainly owing to increasing prevalence of diabetes in this region. According to, Centers for Disease Control and Prevention (CDC), in U.S. more than 100 million adults are suffering from diabetes or prediabetes. However, the Asia-Pacific region is projected to be the fastest-growing over the period 2021-2026. This is owing to rising expenditure on healthcare coupled with rising ageing population.

Retinal Biologics Market Drivers

Increasing Prevalence of Diabetes and Macular Degeneration (AMD)

Increasing prevalence of diabetes and macular degeneration (AMD) across the globe is driving the growth of Retinal Biologics market. According to, World Health Organization (WHO), in worldwide around 422 million people living with diabetes and 1.6 million death cause by diabetes. Moreover, According to, American Academy of Ophthalmology, around 1.5 million North American people suffering from macular degeneration (AMD) is also set to increase the market growth. 

Rising Research and Development 

Increase in research and development of advanced technology for Retinal Biologics is also driving the market. New product development and innovation in formulations and drug designing in retinal biologics for instance, in 2019, Ocugen, Inc., partnered with CanSino Biologics for development of product based on gene therapy for treatment of inherited retinal diseases. Also, advanced drug formulations such as adoption of VEGF-A antagonist class of drugs is also set to the growth of Retinal Biologics Market. 

Retinal Biologics Market Challenges 

Side effect of Retinal Biologics cause retinal tear, illness, and eye pain is challenging the market. Along with this, high initial investment and stringent regulatory processes are also further challenging the growth of the market. 

COVID-19 Impact

Moreover, the outbreak of COVID-19 around the world has impacted all industries including healthcare industry. Covid- 19 affects the Retinal Biologics market including drastic reduction in demand owing to lack of visits to healthcare facilities such as hospitals and clinics. Also the widespread of coronavirus has affected workforce and staffing, creating procedural prioritisation. These affect Retinal Biologics market by cancellation of scheduled visit for medical care at hospitals for patient concerns.

Retinal Biologics Market Industry Outlook

Product launches, Merger & Acquisitions, Joint Ventures and R&D activities are key strategies adopted by players in the Retinal Biologics Market. Retinal Biologics top 10 companies are Oxurion NV, MeiraGTx Limited, AbbVie Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis International AG, Amgen, Inc., Johnson & Johnson, Spark Therapeutics and Regeneron Pharmaceuticals, Inc.

Acquisitions/Product Launches:

  • In September 2020, Samsung Biologics partnered with Kanaph Therapeutics to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
  • In September 2019, Ocugen Inc. partnered with CanSiono Biologics for development of Ocugens’s first gene therapy product, OCU400 for treatment of inherited retinal diseases

Relevant Reports:

Report Code: ESR 0054

Report Code:  HCR 0568

For more Lifesciences and Healthcare Market reports, Please click here
1. Retinal Biologics Market - Overview
    1.1 Definitions and Scope
2. Retinal Biologics Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Drug Class
    2.3 Key trends by Diseases Indication
    2.4 Key trends by Distribution Channel
    2.5 Key trends by Geography
3. Retinal Biologics Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Retinal Biologics Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Retinal Biologics Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6.  Retinal Biologics Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Retinal Biologics Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Retinal Biologics Market – By Drug Class(Market Size –$Million/$Billion)
    8.1 VEGF-A Antagonist
    8.2 TNF-a Inhibitor
9. Retinal Biologics Market – By Disease Indication(Market Size –$Million/$Billion)
    9.1 Oral Macular Degeneration
    9.2 Parenteral Diabetic Retinopathy
    9.3 Uveitis
    9.4 Others
10. Retinal Biologics Market - By Distribution Channel(Market Size –$Million/$Billion)
    10.1 Hospital
    10.2 Pharmacies
    10.3 Specialty clinics
    10.4 Online pharmacies
    10.5 Others
11. Retinal Biologics Market - By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Others
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Retinal Biologics Market - Entropy
13. Retinal Biologics Market – Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Retinal Biologics Market – Key Company List by Country Premium Premium
15. Retinal Biologics Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Competition Analysis Market 2019-2024 ($M)
2.Global Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
2.1 by Drug Class, Market 2019-2024 ($M) - Global Industry Research
2.1.1 VEGF-A antagonist Market 2019-2024 ($M)
2.1.2 TNF- inhibitor Market 2019-2024 ($M)
2.2 By Drug Class, Market 2019-2024 ($M) - Global Industry Research
3.Global Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
3.1 by Indication, Market 2019-2024 ($M) - Global Industry Research
3.1.1 Macular degeneration Market 2019-2024 ($M)
3.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
3.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
3.1.4 Uveitis Market 2019-2024 ($M)
3.2 By Indication, Market 2019-2024 ($M) - Global Industry Research
4.Global Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
4.1 by Distributional Channel, Market 2019-2024 ($M) - Global Industry Research
4.1.1 Institutional Sales Market 2019-2024 ($M)
4.1.2 Retail Sales Market 2019-2024 ($M)
4.2 By Distributional Channel, Market 2019-2024 ($M) - Global Industry Research
5.Global Competition Analysis Market 2019-2024 (Volume/Units)
6.Global Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 (Volume/Units)
6.1 by Drug Class, Market 2019-2024 (Volume/Units) - Global Industry Research
6.1.1 VEGF-A antagonist Market 2019-2024 (Volume/Units)
6.1.2 TNF- inhibitor Market 2019-2024 (Volume/Units)
6.2 By Drug Class, Market 2019-2024 (Volume/Units) - Global Industry Research
7.Global Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 (Volume/Units)
7.1 by Indication, Market 2019-2024 (Volume/Units) - Global Industry Research
7.1.1 Macular degeneration Market 2019-2024 (Volume/Units)
7.1.2 Diabetic Retinopathy Market 2019-2024 (Volume/Units)
7.1.3 Diabetic Macular Edema Market 2019-2024 (Volume/Units)
7.1.4 Uveitis Market 2019-2024 (Volume/Units)
7.2 By Indication, Market 2019-2024 (Volume/Units) - Global Industry Research
8.Global Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 (Volume/Units)
8.1 by Distributional Channel, Market 2019-2024 (Volume/Units) - Global Industry Research
8.1.1 Institutional Sales Market 2019-2024 (Volume/Units)
8.1.2 Retail Sales Market 2019-2024 (Volume/Units)
8.2 By Distributional Channel, Market 2019-2024 (Volume/Units) - Global Industry Research
9.North America Competition Analysis Market 2019-2024 ($M)
10.North America Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
10.1 by Drug Class, Market 2019-2024 ($M) - Regional Industry Research
10.1.1 VEGF-A antagonist Market 2019-2024 ($M)
10.1.2 TNF- inhibitor Market 2019-2024 ($M)
10.2 By Drug Class, Market 2019-2024 ($M) - Regional Industry Research
11.North America Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
11.1 by Indication, Market 2019-2024 ($M) - Regional Industry Research
11.1.1 Macular degeneration Market 2019-2024 ($M)
11.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
11.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
11.1.4 Uveitis Market 2019-2024 ($M)
11.2 By Indication, Market 2019-2024 ($M) - Regional Industry Research
12.North America Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
12.1 by Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
12.1.1 Institutional Sales Market 2019-2024 ($M)
12.1.2 Retail Sales Market 2019-2024 ($M)
12.2 By Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
13.South America Competition Analysis Market 2019-2024 ($M)
14.South America Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
14.1 by Drug Class, Market 2019-2024 ($M) - Regional Industry Research
14.1.1 VEGF-A antagonist Market 2019-2024 ($M)
14.1.2 TNF- inhibitor Market 2019-2024 ($M)
14.2 By Drug Class, Market 2019-2024 ($M) - Regional Industry Research
15.South America Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
15.1 by Indication, Market 2019-2024 ($M) - Regional Industry Research
15.1.1 Macular degeneration Market 2019-2024 ($M)
15.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
15.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
15.1.4 Uveitis Market 2019-2024 ($M)
15.2 By Indication, Market 2019-2024 ($M) - Regional Industry Research
16.South America Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
16.1 by Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
16.1.1 Institutional Sales Market 2019-2024 ($M)
16.1.2 Retail Sales Market 2019-2024 ($M)
16.2 By Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
17.Europe Competition Analysis Market 2019-2024 ($M)
18.Europe Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
18.1 by Drug Class, Market 2019-2024 ($M) - Regional Industry Research
18.1.1 VEGF-A antagonist Market 2019-2024 ($M)
18.1.2 TNF- inhibitor Market 2019-2024 ($M)
18.2 By Drug Class, Market 2019-2024 ($M) - Regional Industry Research
19.Europe Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
19.1 by Indication, Market 2019-2024 ($M) - Regional Industry Research
19.1.1 Macular degeneration Market 2019-2024 ($M)
19.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
19.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
19.1.4 Uveitis Market 2019-2024 ($M)
19.2 By Indication, Market 2019-2024 ($M) - Regional Industry Research
20.Europe Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
20.1 by Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
20.1.1 Institutional Sales Market 2019-2024 ($M)
20.1.2 Retail Sales Market 2019-2024 ($M)
20.2 By Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
21.APAC Competition Analysis Market 2019-2024 ($M)
22.APAC Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
22.1 by Drug Class, Market 2019-2024 ($M) - Regional Industry Research
22.1.1 VEGF-A antagonist Market 2019-2024 ($M)
22.1.2 TNF- inhibitor Market 2019-2024 ($M)
22.2 By Drug Class, Market 2019-2024 ($M) - Regional Industry Research
23.APAC Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
23.1 by Indication, Market 2019-2024 ($M) - Regional Industry Research
23.1.1 Macular degeneration Market 2019-2024 ($M)
23.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
23.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
23.1.4 Uveitis Market 2019-2024 ($M)
23.2 By Indication, Market 2019-2024 ($M) - Regional Industry Research
24.APAC Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
24.1 by Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
24.1.1 Institutional Sales Market 2019-2024 ($M)
24.1.2 Retail Sales Market 2019-2024 ($M)
24.2 By Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
25.MENA Competition Analysis Market 2019-2024 ($M)
26.MENA Retinal Biologics Market Analysis and Forecast , By Drug Class Market 2019-2024 ($M)
26.1 by Drug Class, Market 2019-2024 ($M) - Regional Industry Research
26.1.1 VEGF-A antagonist Market 2019-2024 ($M)
26.1.2 TNF- inhibitor Market 2019-2024 ($M)
26.2 By Drug Class, Market 2019-2024 ($M) - Regional Industry Research
27.MENA Retinal Biologics Market Analysis and Forecast , By Indication Market 2019-2024 ($M)
27.1 by Indication, Market 2019-2024 ($M) - Regional Industry Research
27.1.1 Macular degeneration Market 2019-2024 ($M)
27.1.2 Diabetic Retinopathy Market 2019-2024 ($M)
27.1.3 Diabetic Macular Edema Market 2019-2024 ($M)
27.1.4 Uveitis Market 2019-2024 ($M)
27.2 By Indication, Market 2019-2024 ($M) - Regional Industry Research
28.MENA Retinal Biologics Market Analysis and Forecast , By Distributional Channel Market 2019-2024 ($M)
28.1 by Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research
28.1.1 Institutional Sales Market 2019-2024 ($M)
28.1.2 Retail Sales Market 2019-2024 ($M)
28.2 By Distributional Channel, Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Retinal Biologics Market Revenue, 2019-2024 ($M)
2.Canada Retinal Biologics Market Revenue, 2019-2024 ($M)
3.Mexico Retinal Biologics Market Revenue, 2019-2024 ($M)
4.Brazil Retinal Biologics Market Revenue, 2019-2024 ($M)
5.Argentina Retinal Biologics Market Revenue, 2019-2024 ($M)
6.Peru Retinal Biologics Market Revenue, 2019-2024 ($M)
7.Colombia Retinal Biologics Market Revenue, 2019-2024 ($M)
8.Chile Retinal Biologics Market Revenue, 2019-2024 ($M)
9.Rest of South America Retinal Biologics Market Revenue, 2019-2024 ($M)
10.UK Retinal Biologics Market Revenue, 2019-2024 ($M)
11.Germany Retinal Biologics Market Revenue, 2019-2024 ($M)
12.France Retinal Biologics Market Revenue, 2019-2024 ($M)
13.Italy Retinal Biologics Market Revenue, 2019-2024 ($M)
14.Spain Retinal Biologics Market Revenue, 2019-2024 ($M)
15.Rest of Europe Retinal Biologics Market Revenue, 2019-2024 ($M)
16.China Retinal Biologics Market Revenue, 2019-2024 ($M)
17.India Retinal Biologics Market Revenue, 2019-2024 ($M)
18.Japan Retinal Biologics Market Revenue, 2019-2024 ($M)
19.South Korea Retinal Biologics Market Revenue, 2019-2024 ($M)
20.South Africa Retinal Biologics Market Revenue, 2019-2024 ($M)
21.North America Retinal Biologics By Application
22.South America Retinal Biologics By Application
23.Europe Retinal Biologics By Application
24.APAC Retinal Biologics By Application
25.MENA Retinal Biologics By Application